People · Operator
Named in public records as an officer, director or promoter · active 2009–2017 · Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alimera Sciences Inc | — | Pharmaceuticals | Series C | $173.8M | $1.1B | 2009 |
| Cardlytics, Inc. | — | Other Technology | Series A | $11.9M | $331.2M | 2017 |
Bryce Youngren at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bryce Youngren on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Johnson | 1 | 22 |
| David Adams | 1 | 14 |
| Brian Halak | 1 | 10 |
| JOHN BALEN | 1 | 8 |
| David Evans | 1 | 6 |
| Brian K. Halak | 1 | 5 |
| Mark Brooks | 1 | 5 |
| Anders Hove | 1 | 4 |
| John Klinck | 1 | 4 |
| Mary T. Szela | 1 | 4 |
| Scott Grimes | 1 | 3 |
| Peter J. Pizzo III | 1 | 3 |
| C. Daniel Myers | 1 | 2 |
| Tony Weisman | 1 | 2 |
| Lynne Laube | 1 | 2 |
| Peter J. Pizzo | 1 | 2 |
| Calvin W. Roberts | 1 | 2 |
| Richard S. Eiswirth | 1 | 1 |
| Glen S. Bradley | 1 | 1 |
| Kenneth Green | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.